Bronchiolitis recovery and the use of High Efficiency Particulate Air (HEPA) Filters (The BREATHE Study): study protocol for a multi-center, parallel, double-blind, randomized controlled clinical trial
- PMID: 38504367
- PMCID: PMC10953277
- DOI: 10.1186/s13063-024-08012-0
Bronchiolitis recovery and the use of High Efficiency Particulate Air (HEPA) Filters (The BREATHE Study): study protocol for a multi-center, parallel, double-blind, randomized controlled clinical trial
Abstract
Background: Acute viral bronchiolitis is the most common reason for hospitalization of infants in the USA. Infants hospitalized for bronchiolitis are at high risk for recurrent respiratory symptoms and wheeze in the subsequent year, and longer-term adverse respiratory outcomes such as persistent childhood asthma. There are no effective secondary prevention strategies. Multiple factors, including air pollutant exposure, contribute to risk of adverse respiratory outcomes in these infants. Improvement in indoor air quality following hospitalization for bronchiolitis may be a prevention opportunity to reduce symptom burden. Use of stand-alone high efficiency particulate air (HEPA) filtration units is a simple method to reduce particulate matter ≤ 2.5 µm in diameter (PM2.5), a common component of household air pollution that is strongly linked to health effects.
Methods: BREATHE is a multi-center, parallel, double-blind, randomized controlled clinical trial. Two hundred twenty-eight children < 12 months of age hospitalized for the first time with bronchiolitis will participate. Children will be randomized 1:1 to receive a 24-week home intervention with filtration units containing HEPA and carbon filters (in the child's sleep space and a common room) or to a control group with units that do not contain HEPA and carbon filters. The primary objective is to determine if use of HEPA filtration units reduces respiratory symptom burden for 24 weeks compared to use of control units. Secondary objectives are to assess the efficacy of the HEPA intervention relative to control on (1) number of unscheduled healthcare visits for respiratory complaints, (2) child quality of life, and (3) average PM2.5 levels in the home.
Discussion: We propose to test the use of HEPA filtration to improve indoor air quality as a strategy to reduce post-bronchiolitis respiratory symptom burden in at-risk infants with severe bronchiolitis. If the intervention proves successful, this trial will support use of HEPA filtration for children with bronchiolitis to reduce respiratory symptom burden following hospitalization.
Trial registration: NCT05615870. Registered on November 14, 2022.
Keywords: Air filtration; Bronchiolitis; HEPA; Indoor air quality; PM2.5; Particulate matter.
© 2024. The Author(s).
Conflict of interest statement
Jessica Snowden, MD, discloses a relevant financial relationship with the ineligible company Pfizer. Dr. Snowden is a consultant for the Pfizer company; however, all potential conflicts of interest have been mitigated. The other authors have no competing interests.
Similar articles
-
Asthma randomized trial of indoor wood smoke (ARTIS): rationale and methods.Contemp Clin Trials. 2012 Sep;33(5):1080-7. doi: 10.1016/j.cct.2012.06.006. Epub 2012 Jun 23. Contemp Clin Trials. 2012. PMID: 22735495 Free PMC article. Clinical Trial.
-
Efficacy of HEPA Air Cleaner on Improving Indoor Particulate Matter 2.5 Concentration.Int J Environ Res Public Health. 2022 Sep 13;19(18):11517. doi: 10.3390/ijerph191811517. Int J Environ Res Public Health. 2022. PMID: 36141811 Free PMC article.
-
Effect of School Integrated Pest Management or Classroom Air Filter Purifiers on Asthma Symptoms in Students With Active Asthma: A Randomized Clinical Trial.JAMA. 2021 Sep 7;326(9):839-850. doi: 10.1001/jama.2021.11559. JAMA. 2021. PMID: 34547084 Free PMC article. Clinical Trial.
-
Should homes and workplaces purchase portable air filters to reduce the transmission of SARS-CoV-2 and other respiratory infections? A systematic review.PLoS One. 2021 Apr 29;16(4):e0251049. doi: 10.1371/journal.pone.0251049. eCollection 2021. PLoS One. 2021. PMID: 33914823 Free PMC article.
-
Effectiveness of indoor allergen reduction in asthma management: A systematic review.J Allergy Clin Immunol. 2018 May;141(5):1854-1869. doi: 10.1016/j.jaci.2018.02.001. Epub 2018 Feb 13. J Allergy Clin Immunol. 2018. PMID: 29452202
References
-
- Pfuntner A, Wier LM, Stocks C. Healthcare cost and utilization project (HCUP) statistical briefs. Rockville: Agency for Healthcare Research and Quality (US); 2006. Most frequent conditions in U.S. hospitals, 2010: statistical brief #148. 2013 Jan. - PubMed
-
- Bisgaard H, Flores-Nunez A, Goh A, Azimi P, Halkas A, Malice MP, Marchal JL, Dass SB, Reiss TF, Knorr BA. Study of montelukast for the treatment of respiratory symptoms of post-respiratory syncytial virus bronchiolitis in children. Am J Respir Crit Care Med. 2008;178(8):854–860. doi: 10.1164/rccm.200706-910OC. - DOI - PubMed
Publication types
MeSH terms
Substances
Associated data
Grants and funding
- UG1 OD024945/OD/NIH HHS/United States
- UG1 OD030016/OD/NIH HHS/United States
- UG1 OD024943/OD/NIH HHS/United States
- UG1 OD024947/OD/NIH HHS/United States
- UG1 OD024942/OD/NIH HHS/United States
- P20 GM130418/GM/NIGMS NIH HHS/United States
- UG1 OD024946/OD/NIH HHS/United States
- UG1 OD024955/OD/NIH HHS/United States
- UG1 OD024953/OD/NIH HHS/United States
- UG1 OD024950/OD/NIH HHS/United States
- UG1 OD024952/OD/NIH HHS/United States
- UG1 OD024951/OD/NIH HHS/United States
- UG1 OD024948/OD/NIH HHS/United States
- UG1 OD024959/OD/NIH HHS/United States
- U24 OD024957/OD/NIH HHS/United States
- UG1 OD024954/OD/NIH HHS/United States
- UG1 OD024944/OD/NIH HHS/United States
- P20GM130418/GM/NIGMS NIH HHS/United States
- UG1 OD030019/OD/NIH HHS/United States
- UG1 OD024956/OD/NIH HHS/United States